Literature Scan

Literature Scan

New and noteworthy research from the medial literature landscape

Adding Pneumatic Compression to Heparin Therapy Does Not Reduce DVT in Critically Ill Patients

According to results from the PREVENT trial, adjunctive pneumatic compression plus pharmacologic thromboprophylaxis did not lower the risk of new lower-limb deep vein thrombosis...

Ibrutinib Plus Venetoclax Leads to High Rates of MRD Negativity in Frontline CLL

The combination of ibrutinib with venetoclax – two agents that have been approved for the treatment of chronic lymphocytic leukemia (CLL) – led to...

Daratumumab Combination Extends Progression-Free Survival for Transplant-Ineligible Myeloma

In patients with newly diagnosed multiple myeloma (MM) who were ineligible for autologous hematopoietic cell transplantation (AHCT), adding daratumumab to a regimen of lenalidomide...

Tagraxofusp Leads to High Response Rates in Blastic Plasmacytoid Dendritic Cell Neoplasm

Ninety percent of patients with previously untreated blastic plasmacytoid dendritic cell neoplasm (BPDCN) responded to treatment with tagraxofusp, a CD123-targeted agent previously known as...

Study Finds Standard R-CHOP Bests Dose-Adjusted EPOCH-R in DLBCL

In an update from the phase III intergroup Alliance/CALGB 50303 trial, treatment with frontline dose-adjusted (DA) EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab) failed...

Early Phase Trial Shows PB2452 Immediately Reverses Ticagrelor’s Antiplatelet Activity

The monoclonal antibody fragment PB2452 effectively and immediately reversed the antiplatelet effects of ticagrelor in healthy volunteers, according to results from a phase I...

Is There a Role for AHCT Consolidation in MCL in the Rituximab Era?

The availability of rituximab-containing induction regimens for patients with mantle cell lymphoma (MCL) has improved outcomes, but younger, transplant-eligible patients may benefit from consolidative...

No Benefit in Adding Rituximab to MBVP in CNS Lymphoma

Results from a phase III trial suggest there is no survival benefit of adding the anti-CD20 monoclonal antibody rituximab to a standard methotrexate-based chemotherapy...

Five Decades of Experience With MPNs: Characterizing Survival and Outcomes

A report based on data from more than 3,000 patients with myeloproliferative neoplasms (MPNs) evaluated at the Mayo Clinic in Rochester, Minnesota, over 50...

Adolescent and Young Adult Cancer Survivors Face Higher Risk of Second Cancers

People who were diagnosed with cancer as adolescents or young adults (AYAs) have an excess risk of developing a subsequent primary neoplasm later in...
Advertisement

Current Issue

July 2019 Bonus Mid-Year Edition, Volume 5, Issue 9

This issue features a look at research espionage, coverage from the ASCO and EHA annual meetings, and more.